Kenvue (KVUE): Multiplikator Forward P/S
Kenvue Inc. (KVUE) dominates the consumer health segment with global brands Tylenol and Listerine. The forward price-to-sales ratio visualizes these positions, where the value 1.70 captures the metric level. Such stability in staple goods sales guarantees predictable income. Consequently, a powerful ecosystem of consumer habits has formed, although talc-related litigation remains a constraining factor.
Rincian metrik lan analitis perusahaan Kenvue Health (KVUE)
- rega pasar lan target rega analis:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Kenvue Inc.|KVUE - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Kenvue Inc.|KVUE - Utang kumulatif perusahaan|Utang marang nilai buku Kenvue Health|KVUE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Kenvue|Likuiditas cepet kenvue.com
- data bathi bisnis lan rasio investasi:
KVUE - Bathi perusahaan|Proyeksi bathi mangsa ngarep Kenvue Inc.|KVUE - Koefisien rega marang bathi|Prakiraan rega marang bathi Kenvue Corp|KVUE - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Kenvue Health|KVUE - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Kenvue|KVUE - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan kenvue.com|KVUE - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Kenvue Inc.
- indikator dodolan lan pendapatan:
Analisis wiwitan perusahaan:Kenvue (KVUE)
Stable demand for Kenvue Inc. (KVUE) consumer staples ensures high cash flow predictability. The forward P/S metric relates current market capitalization to expected sales volume, allowing investors to determine the extent of overpayment for future earnings. Analyzing the trend of this metric helps investors recognize the risk of asset overheating in a timely manner and select the optimal entry point for long-term holding.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Haleon HLN|Multiplikator Forward P/S Verona Pharma PLC VRNA|Jyong Biotech Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ligand Corp|Amneal Pharmaceuticals (AMRX) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan PRGO|Multiplikator forward rega marang pendapatan ALVO|Rasio rega marang prakiraan pendapatan LQDA|Multiplikator forward rega marang pendapatan GLPG (Galapagos Genomics)|Multiplikator Forward P/S ANI Pharmaceuticals Corp (ANIP)|Multiplikator Forward P/S MNKD (MannKind Corporation)|amphastar.com (AMPH) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|PCRX: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SPRY (ARS Pharmaceuticals Inc)|TBPH: Multiplikator Forward P/S|AQST - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan scPharmaceuticals, Inc.|Kapitalisasi marang prakiraan pendapatan TECX (Tectonic)|Multiplikator Forward P/S TNXP|Multiplikator forward rega marang pendapatan sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake BioHarvest Sciences Inc (BHST)|EXOZ - Rasio rega marang prakiraan pendapatan|ORMP - Multiplikator Forward P/S|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|HYFT (MindWalk Holdings, Inc.) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ABVC|Multiplikator Forward P/S Cumberland Corp|Multiplikator Forward P/S QNTM|FGEN - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Telomir Pharmaceuticals, Inc. TELO|RANI (Rani Therapeutics Holdings) - Rega mangsa ngarep marang pendapatan|Synergy CHC Corporation - Multiplikator Forward P/S|Rega forward marang dodolan RLYB (Rallybio Corporation)|LEXX: Multiplikator Forward P/S|pulmatrix.com (PULM) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|APM: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|Multiplikator forward rega marang pendapatan Impact BioMedical, Inc. IBO|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Multiplikator Forward P/S cbdMD Inc. YCBD|PRFX: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CYTO (Altamira Therapeutics)|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Multiplikator forward rega marang pendapatan PIRS|PROC (procapsgroup.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|TFF Pharmaceuticals, Inc (TFFP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep
